Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » ERS Genomics, FASMAC Sign Deal to Commercialize CRISPR-Cas9 Research Reagents in Japan

ERS Genomics, FASMAC Sign Deal to Commercialize CRISPR-Cas9 Research Reagents in Japan

Oct 14, 2020
|
staff reporter

NEW YORK – ERS Genomics said on Wednesday that it has signed a licensing agreement granting Japanese biotech company FASMAC access to ERS's CRISPR-Cas9 patent portfolio, and the right to use the technology to commercialize tools and reagents associated with it.

Financial details of the transaction were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Funds Sought for Vaccine Distribution

The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.

Virus Variant From Spain Now Across UK

The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.

Unexpected Loss

A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.

Science Papers on Long Human-Canine Relationship, Population History of Early East Asians, More

In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.

What's Popular?

In Business News

  1. Illumina Q3 Revenues Down 12 Percent

  2. Qiagen, Phase Genomics Ink US Licensing Agreement for Hi-C Sequencing Technloogy

  3. Bio-Rad Q3 Revenues Jump 15 Percent

  4. Opko Health Q3 Revenues Up 87 Percent

  5. Biocartis, Exact Sciences Terminate Oncotype DX Agreement

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.